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Abstract
Background: GLV-1h68 is an attenuated recombinant vaccinia virus (VACV) that selectively colonizes
established human xenografts inducing their complete regression.
Results: Here, we explored xenograft/VACV/host interactions in vivo adopting organism-specific
expression arrays and tumor cell/VACV in vitro comparing VACV replication patterns. There were no
clear-cut differences in vitro among responding and non-responding tumors, however, tumor rejection was
associated in vivo with activation of interferon-stimulated genes (ISGs) and innate immune host's effector
functions (IEFs) correlating with VACV colonization of the xenografts. These signatures precisely
reproduce those observed in humans during immune-mediated tissue-specific destruction (TSD) that
causes tumor or allograft rejection, autoimmunity or clearance of pathogens. We recently defined these
common pathways in the "immunologic constant of rejection" hypothesis (ICR).
Conclusion: This study provides the first prospective validation of a universal mechanism associated with
TSD. Thus, xenograft infection by oncolytic VACV, beyond offering a promising therapy of established
cancers, may represent a reliable pre-clinical model to test therapeutic strategies aimed at modulating the
central pathways leading to TSD; this information may lead to the identification of principles that could
refine the treatment of cancer and chronic infection by immune stimulation or autoimmunity and allograft
rejection through immune tolerance.
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In the past, we applied inductive reasoning [1] to identify
immunologic signatures associated with tumor rejection,
clearance of pathogen, acute allograft rejection or autoim-
munity. This exercise leads to the formulation of the
"immunologic constant of rejection" (ICR) hypothesis:
"immune-mediated tissue specific destruction (TSD) follows a
common final pathway independent of the originating cause
and the disease context" [2]. 4 axioms were proposed at the
basis of the ICR: i) TSD does not necessarily occur because
of non-self recognition but also occurs against self or
quasi-self; ii) the requirements for the induction of a cog-
nate immune response differ from those necessary for the
activation of an effector one; iii) although the prompts
leading to TSD vary in distinct pathologic states, the effec-
tor immune response converges into a single mechanism;
and iv) adaptive immunity participates as a tissue-specific
trigger, but it is not always sufficient or necessary. Here,
we applied deductive reasoning to test whether immuno-
logic markers of ICR could be predictably observed in a
controllable experimental model. We selected a promis-
ing pre-clinical endeavor where the systemic administra-
tion of oncolytic VACV induces xenograft regression in
immune deficient mice through an, at least in part, immu-
nologically-mediated mechanism. In addition, we tested
the validity of the fourth axiom, which postulates, in con-
cordance with others' observations, that tumor rejection
does not require adaptive immunity [3].
Systemic delivery of oncolytic viruses leads to their spe-
cific localization to established tumors and to viral repli-
cation followed by oncolysis [4]. VACV, in particular,
possesses strong antitumor properties [5] while its history
as vaccine against smallpox proves it safe in humans. Fur-
ther attenuation by disruption of non essential viral genes
such as J2R (coding for thymidine kinase) [6,7] and A56R
(coding for haemagglutinin) [8] increased the therapeutic
potential of VACV as an oncolytic agent. In addition, the
same construct could be used for tumor-specific delivery
of light-emitting proteins for real-time imaging [9] or
therapeutic proteins such as tumor suppressors [10], anti-
angiogenesis factors [11] or immune modulators [12].
The design of a VACV construct, GLV-1h68, derived from
LIVP wild-type strain by insertion of 3 expression cassettes
encoding Renilla luciferase-Aequorea green fluorescent
fusion protein (RUC-GFP), b-galactosidase and b-glu-
coronidase [9,13] lead to a highly attenuated oncolytic
virus capable of targeting established human xenografts.
The ability to replicate specifically within tumors and to
leave non malignant tissues virus-free makes GLV-1h68
systemic administration a promising pre-clinical tool
capable of safely eradicating pancreatic cancer [14], malig-
nant pleural mesothelioma [15], breast carcinoma GI-
101A xenografts [13] and anaplastic thyroid cancer [16].
Eradication of established human breast cancer GI-101A
xenografts can be reproducibly induced in nude mice
injected intravenously with 1 × 107 plaque forming units
(PFU) of GLV-1h68. Tumor eradication occurs in 95% of
treated animals within 130 days from injection and it is
associated with pristine tropism of GLV-1h68 for the
xenograft and lack of systemic toxicity or mortality.
Because GLV-1h68 encodes a luciferase reporter, it is pos-
sible to estimate kinetically virus titers in tumor
xenografts and correlate this parameter with treatment
outcome [13].
Experimental observations demonstrated a tight relation-
ship between virus replication within the tumor xenograft
and response to oncolytic treatment. However, the mech-
anisms leading to tumor regression by oncolytic virus
remain unknown [17,18]. While it is possible that a direct
oncolytic activity may be responsible for tumor regres-
sion, it is also possible that tumor eradication is the result
of a complex interplay among virus, cancer cells and the
host [19]. Expression profiling of xenografts responding
to treatment with GLV-1h68 based on a mouse-specific
platform and hence representative of the host's response
to the GLV-1h68-infected human xenograft suggested that
their eradication is associated with the over-expression of
signatures consistent with innate immune defense activa-
tion. These signatures are inclusive of interferon-stimu-
lated genes (ISGs) such as STAT-1 and IRF-7, chemokines
(Ccl2, Ccl9, Ccl27, Cxcl9, Cxcl10, Cxcl12), chemokine
receptors (Ccr2), interleukins (IL-18) and innate immune
effector functions (IEF) [13]. The participation of immune
cells was supported by immunohistochemistry, which
demonstrated active peri-tumoral and intra-tumoral infil-
tration of monocytes in treated samples [13]; however,
the specificity of the association between xenograft eradi-
cation and immune activation could not be determined
since non-responding xenografts were not included in the
previous analysis.
We hypothesized that in this model the eradication of
responding xenografts is, at least in part, mediated
through innate immune mechanisms and, as a conse-
quence, this model could provide important insights
about the role played by innate immunity in mediating
tissue rejection in the immune incompetent host [2].
Recent animal studies suggest that immune-mediated
eradication of syngeneic tumors is independent of adap-
tive immune responses [3], and the involvement of cyto-
toxic T cells may provide primarily help for the in situ
targeting and/or activation of innate immune effector
cells [20]. Therefore, progression of events leading to
xenograft rejection in a mouse model deprived of adop-
tive immune function may simplify the identification of
the requirements for tumor rejection and, more broadly,
those necessary for TSD [2].Page 2 of 22
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tion characteristics specifically correlated with oncolytic
GLV-1h68-mediated tumor rejection, we tested human
cancer cell lines of different tissue derivation for their in
vitro permissivity to GLV-1h68 replication, their in vivo
colonization and their susceptibility to VACV-mediated
eradication. In addition, we used 3 array platforms to
characterize VACV, human (tumor cells) and mouse
(inflammatory cells) gene expression in GLV-1h68-
infected xenografts in vivo. The results demonstrated that
tumor rejection is associated with activation of innate
immune mechanisms in the host that recapitulate faith-
fully the biological pathways observed in association with
immune-mediated TSD in humans [2]. Thus, this model
suggests that immune rejection does not depend upon
adaptive immunity as long as the initiating mechanism
(in this case selective viral localization at the tumor) is
specific to a particular tissue. The demonstration that
immune deficient mice can reject human xenograft fol-
lowing a pathway common to other human immune
pathologies suggests that the ICR is a universal phenome-
non across species and may represent a target for immune
modulation in the context of various diseases.
Results
Variability of xenograft responses to the systemic 
administration of GLV-1h68
A panel of human cancer cell lines of different histological
derivation was tested for their sensitivity to the oncolytic
activity of intra-venously injected GLV-1h68 [21-25]. 2
characteristic patterns were identified: some cell lines pro-
gressively continued their growth independent of therapy
(i.e. HT-29), while others followed 3 growth phases: first,
a slightly faster growth of infected compared to control
tumors, then a period of no or minimal growth, and
finally, complete regression (i.e. Gl-101A) [13] (Figure
1A). Tumor growth or regression patterns were cell line-
specific, highly reproducible, and independent of number
of cancer cells administered or dose of GLV-1h68 injected
[13]. A therapeutic index (T.I.) was calculated to provide a
single parameter descriptive of each cell line's responsive-
ness to VACV therapy by integrating the areas between the
median growth of control and treated xenografts (eight
animals in each group in all experiments described here
and thereafter) (Table 1). The same cell lines were sub-
jected to an in vitro assay in which their permissivity to
GLV-1h68 replication was tested (data not shown, see
Additional file 1). We observed that 3 of 3 cell lines that
resisted replication during the first 24 hours following
infection (MDA-MB-231, SiHa and NCI-H1299) uni-
formly produced xenografts partially or non-responding
to VACV therapy in vivo. However, 8 of 10 cell lines that
allowed viral replication in the first 24 hours yielded
xenografts responsive in vivo to VACV treatment while 2
(HT-29 and 1936-MEL) yielded xenografts that did not
respond. The relationship between the permissivity of a
given cell line to in vitro replication of GLV-1h68 and the
in vivo responsiveness of the corresponding xenograft was
significant (Fisher exact test p2-value = 0.005) but not
absolute.
Of particular interest was a pair of cell lines: the colorectal
carcinoma HT-29 (non responding) and the breast aden-
ocarcinoma GI-101A (responding) cell lines [13] that dis-
played in vitro a similar degree of permissivity to VACV
replication. Since the distinct behavior of the 2 cell lines
could have been due to their diverse ontogeny [26], we
tested a pair of autologous melanoma cell lines, 888-MEL
and 1936-MEL derived from the same progenitor cell
clone though established from 2 metachronous metas-
tases [24,27]; 888-MEL was generated in 1989 during the
earlier stage of disease at a time when the patient under-
went a complete remission following adoptive transfer of
tumor infiltrating lymphocytes; 1936-MEL was expanded
12 years later from a metastasis excised at a time when the
patient was rapidly progressing and did not respond to
further therapy [24]. The cell lines displayed the same
degree of permissivity in vitro to GLV-1h68 replication,
but yielded xenografts with disparate sensitivity to VACV
treatment in vivo (Table 1). These data suggest that even
in autologous systems responsiveness is related to biolog-
ical characteristics of the tumors that are independent of
their ontogeny, and are more likely related to evolving
phenotypes during the natural history of the disease.
We then analyzed VACV replication in vivo in a respond-
ing (GI-101A), a non-responding (HT-29) and another
presently less characterized (PC-3) line. Twenty-one days
post GLV-1h68 administration; viral titers were lower in
non-responding xenografts (Figure 1B). The difference
was less pronounced after 42 days, suggesting that the lack
of responsiveness to oncolytic therapy may be associated
with delayed but not completely absent VACV replication.
Transcriptional profiling of VACV/tumor/host interactions
To gain better insights on the mechanisms governing
xenograft rejection, we compared simultaneously the
transcriptional patterns of VACV, human cancer cells and
mouse host cells in responding and non-responding
xenografts excised at time points associated with tumor
and viral growth (day 21 after injection) or at the plateau
phases preceding tumor rejection (day 42). This was
achieved by the adoption of organism-specific platforms.
Transcriptional differences between xenografts 
responding or non-responding to systemic GLV-1h68 
administration: the VACV signatures
VACV-gene expression was assessed by a custom-made
VACV array platform to compare the expression of VACV
transcripts in vivo in the responding GI-101A and the non-Page 3 of 22
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delayed in vivo replication) xenografts. VACV transcrip-
tional patterns correlated perfectly with viral titers. More-
over, in all cell lines there was a perfect correlation
between RUC-GFP expression and overall expression of
VACV genes (R2 = 0.90) suggesting that this reporter gene
accurately represents GLV-1h68 replication (Figure 1C).
Variation in VACV gene expression was observed among
cell lines or among xenografts derived from the same cell
line. Furthermore, a clear dichotomy was observed in
transcriptional patterns: VACV transcripts were either all
up regulated or completely silent suggesting that the tran-
sition from early to late VACV gene expression occurred in
rapid succession that could not be discriminated by the
time points examined. Most GI-101A xenografts demon-
strated early in vivo replication with 3 out of 4 expressing
Characterization of human xenografts and Vaccinia Virus signaturesFigure 1
Characterization of human xenografts and Vaccinia Virus signatures. (A) Representative growth curves (n = 8 ani-
mals) for 2 xenografts from HT-29 and GI-101A cell lines; red dots represent control, green boxes the post treatment groups; 
for further details about the xenograft model refer to references [9,13]. (B) Viral titer (PFU/gram of xenograft; n = 4) compar-
ing the permissivity of 3 xenografts derived from GI-101A, HT-29 and PC-3 cell line whose responsiveness is under character-
ization 7, 21 and 42 days after GLV-1h68 administration. (C, left) Scatter plot correlating the level of Renilla luciferase-
Aequorea green fluorescent protein messenger RNA expression with the presence call of probes above the set threshold level 
for the VACV expression array platform. VACV gene expression in non-infected PC-3, HT-29 and GI-101A xenografts was 
compared to infected xenografts 1, 7 (GI-101A only), 21 and 42 days before. High presence call (> 40%) in the non-infected 
xenografts could be expected due to the large number of mouse and human housekeeping genes present in the array plat-
form); R2 value refers to the correlation between RUC-GFP expression and number of VACV transcripts significantly up regu-
lated in the same experiment. (C, right) Scatter plot as per panel C, left, comparing in vitro VACV gene expression of GLV-
1h68-infected HT-29 and GI-101A cell lines at 6 and 12 hours with controls. (D) A Venn diagram displays the extent of overlap 
among VACV-specific probes (top) and VACV genes (bottom) differentially expressed by infected GI-101A xenografts at day 
21 and 42 compared with day 1 after GLV-1h68 injection.Page 4 of 22
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contrast, HT-29 suffered delayed replication in vivo with
only a proportion displaying full VACV gene expression at
day 21 (2 of 4 in either case). After 42 days the expression
of VACV genes was turned on only in 1 of 4 HT-29
xenografts. VACV gene expression analysis confirmed lack
of differences in VACV transcriptional patterns in vitro
between HT-29 and GI-101A with 3 out of 3 cell cultures
demonstrating active viral replication in either case in the
first 12 hours after infection (Figure 1C).
Subsequently, comparisons were made between infected
and non-infected GI-101A and HT-29 xenografts. Even
though there might have been better responder/non-
responder pairs to choose from we selected HT-29 tumors
among non-responding cell lines because of its similar in
vitro permissivity to GLV-1h68 that corresponded to a dif-
ferent behavior in vivo and previous characterizations in
our laboratory. A high-stringency (p2-value < 0.005) Stu-
dent t test comparing the number of VACV genes differen-
tially expressed at day 21 or 42 from infected animals with
those from uninfected ones identified significant differ-
ences (multivariate permutation p-value < 0.001) only in
GI-101A xenografts at day 21 and day 42 (Table 2). As pre-
viously discussed, the number of genes differentially
expressed in xenografts with replicating VACV reflected
completely the number of VACV-specific annotations
present in the VACV-array platform demonstrating that
GLV-1h68 replication is either absent or complete in
xenografts at this time point. As to be expected, an almost
complete overlap of VACV probes or genes expressed at
day 21 and 42 was observed in the GI-101A xenografts
(Figure 1D). Notably, a reverse behavior was observed in
the pattern of expression of human house keeping genes
represented in the VACV array platform. The expression of
these genes was profoundly down-regulated in permissive
cell lines suggesting a shut off of cellular metabolism in
infected cells that correlated inversely with viral transcrip-
tion as described by others [28]. It is noteworthy that,
although HT-29 did not display significant up regulation
of VACV genes using the high stringency parameters
adopted here, it displayed a similar trend in gene expres-
sion with mild up-regulation of VACV genes and expres-
sion of GFP messenger RNA in some but not all xenografts
(Figure 1C).
Transcriptional differences between xenografts 
responding or non-responding to systemic GLV-1h68 
administration: the human cancer signatures
A time course analysis evaluating the in vivo effects of viral
replication on the permissive GI-101A human xenografts
was performed using a custom-made 17.5 k human cDNA
array platform [29]. 4 experimental groups of 4 mice each
received systemic GLV-1h68 administration 1, 7, 21 and
42 days before xenograft excision (Figure 2A[30]). The
transcriptional profile of infected GI-101A tumors was
altered significantly by 21 days and increasingly so at 42
days after GLV-1h68 administration. Since the time
course demonstrated that even in permissive xenografts
significant changes occurred only at 21 and 42 days, we
limited the subsequent analysis to these time points.
To better characterize the transcriptional program of
VACV-infected cancer cell lines, we compared responding
(GI-101A) and non-responding (HT-29) xenografts using
a 36 K whole genome, human oligo array platform at day
21 and 42. Multiple dimensional scaling based on the
complete data set demonstrated that infected GI-101A
xenografts (2 darker blue color) segregated completely in
Euclidian space from non-infected xenografts (2 lighter
Table 1: Therapeutic Index (T.I) of responding compared to non-responding xenografts
Responders (R) T.I. Poor/Non-Responders (NR) T.I.
1858-MEL Melanoma 90.1 MDA-MB-231 Breast Adenocarcinoma 21.6
888-MEL Melanoma 88.0 SiHa Cervical Squamous Cell Carcinoma 15.6
MIA PaCa-2 Pancreatic Carcinoma 80.1 1936-MEL Melanoma 13.7
A549 Lung Carcinoma 62.8 NCI-H1299 Breast Adenocarcinoma -2.3
OVCAR-3 Ovarian Adenocarcinoma 56.2 HT-29 Colorectal Carcinoma -19.0
Panc-1 Pancreatic Carcinoma 50.9
DU-145 Prostate Carcinoma 48.4
GI-101A Breast Carcinoma 27.9Page 5 of 22
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Table 2: Number of genes over-expressed in xenografts excised from GLV-1h68 infected animals
Experimental group Days after VACV inj.
VACGLa 520445F, Affymetrix platform VACV only Permutation House keeping (human/mouse) Permutation
(cut off p2-value < 0.005 (unpaired Student t 
test)
(å 219) test p-value (å 337) test p-value
GI-101A 7 0 N.S. 3 N.S.
GI-101A 21 219 < 0.001 (232) < 0.001
GI-101A 42 216 < 0.001 (237) < 0.001
HT-29 21 0 N.S. (3) N.S.
HT-29 42 0 N.S. (10) N.S.
37 K whole genome HUMAN array All genes Permutation
(cut off p2-value < 0.001 (unpaired Student t 
test)
(å 37 K) test p-value
GI-101A 21 136 < 0.05
GI-101A 42 91 < 0.05
HT-29 21 4 N.S.
HT-29 42 10 N.S.
37 K whole genome Mouse array All genes Permutation
(cut off p2-value < 0.001 (unpaired Student t 
test)
(å 37 K) test p-value
GI-101A 21 105 < 0.05
GI-101A 42 1026 < 0.001
HT-29 21 7 N.S.
HT-29 42 14 N.S.
* In parenthesis, genes down-regulated in GLV-1h68-infected animals referring to human/mouse house-keeping genes in the VACV chip
BMC Genomics 2009, 10:301 http://www.biomedcentral.com/1471-2164/10/301blue colors) while HT-29 xenografts intermingled
whether they were from infected or non-infected animals
(Figure 2B).
To test overall differences between xenografts from infected
and non-infected animals, we applied a Student t test (cut-
off p2-value < 0.001) comparing infected to non-infected
GI-101A and HT-29 xenografts. Comparison of GI-101A
identified 1,073 genes differentially expressed between
infected and non-infected xenografts (permutation test p
value = 0). On the contrary, only 9 genes were found to be
differentially expressed by HT-29 xenografts from infected
compared to non-infected animals (permutation test non
significant). Among genes differentially expressed in the
Human Cancer signaturesFigure 2
Human Cancer signatures. (A) Time course analysis of infected GI-101A xenografts (parameters for gene selection; F test 
p-value < 0.005, 80% presence call, ratio of > 2 and false discovery rate < 0.1). Gene distribution is shown based on 893 genes 
of 17,500 present in the human cDNA platform that passed the statistical criteria and presented according to Spearman rank 
correlation. The dashed box outlines the 2 time points most affected by VACV infection. The heat map information is pre-
sented according to the central method for normalization [30]. (B) Multiple dimensional scaling based on the 36 k oligo array 
human platform comparing HT-29 and GI-101 xenografts. (C) Self organizing heat map based on 841 out of 1,073 genes differ-
entially expressed between GI-101A xenografts from infected compared to non-infected mice that passed the standard filter 
conditions (presence call in at least 80% and at least 3 fold ratio change). HT-29 samples are also represented as a reference, 
color coding of samples is as per panel (B). The green bar underlines the genes specifically expressed by Gl-101A xenografts 
from infected animals; the 2 yellow arrows (a) and (b) point at genes who expression was profoundly depressed in xenografts 
from infected animals. (D) Ingenuity pathway analysis showing canonical pathways significantly down-regulated in GI-101A 
xenografts at day 41 following GLV-1h68 injection; IPA analysis based on an unpaired, two-tailed Student t test comparing 
infected to non-infected GI-101A xenografts at day 42 (threshold p2-value < 0.001).Page 7 of 22
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BMC Genomics 2009, 10:301 http://www.biomedcentral.com/1471-2164/10/301GI-101A xenografts from GLV-1h68 infected animals, the
large majority were down-regulated, particularly, in
xenografts excised at day 42 suggesting that viral replication
depresses cellular metabolism (Figure 2C, yellow arrows
annotated with a and b) consistent with the down-regula-
tion of house keeping genes observed in the VACV-chip.
Ingenuity pathway analysis (IPA) demonstrated that,
among the canonical pathways, the top 10 categories of
down-regulated genes represented depressed cellular func-
tion including alterations in oxidative pathways, mito-
chondrial dysfunction, and disruption of purine,
pyrimidine and amino acid metabolism (Figure 2D). Inter-
estingly, a smaller cluster of genes was over-expressed in GI-
101A xenografts from infected animals (green bar, Figure
2C, Table 2). Among these genes, allograft inflammatory
factor-1 (AIF-1), the tissue inhibitor of metalloproteinase 2
(TIMP-2) and the IL-2 receptor common g  chain were up
regulated. Moreover, a multivariate analysis (F test, p-value
cutoff < 0.001) based on the oligo arrays comparing the 4
groups at day 21 and 42 (HT-29 and GI-101A in infected
and non-infected mice) identified respectively 2,241 and
1,984 clones differentially expressed among the 4 groups.
Analysis with the 17 k cDNA arrays similarly identified
1,467 cDNA clones representative of the 4 categories at day
42. In both platforms, most of the differences in expression
pattern involved tumor cell specific genes and both plat-
forms segregated the HT-29 xenografts from GI-101A
xenografts independent of GLV-1h68 administration
according to their different ontogeny; a phenomenon we
have previously described [26]; however, a subgroup of
genes was observed to be specific for GI-101A infected
xenografts. The GLV-1h68 infection-specific signatures
were enriched for up regulated genes associated with
immune function with a significantly higher than expected
frequency (1.88) according to GeneOntology assignment.
Among the genes up-regulated in the GI-101A xenografts
excised from GLV-1h68 infected mice, several were associ-
ated with activation of innate immune mechanisms includ-
ing the Toll-like receptor (TLR)-2, the interferon regulatory
factor (IRF)-7, signal transducer and activator of T cell
(STAT)-3 and tumor necrosis factor (TNF)-a. This enrich-
ment was not observed in oligo-based arrays suggesting
that these signatures could be potentially attributed to host
infiltrating immune cells whose genes could cross-hybrid-
ize to the less stringent cDNA array probes; this could occur
in spite of the intensity filter adjustment for sequences with
high mouse to human similarity. Sequence verification,
demonstrated that only STAT-3 and IRF-7 were indeed
expressed by human cells while the other genes were mouse
transcripts cross hybridizing to the cDNA probes but not to
the more stringent oligo-probes (see Additional file 2).
In summary, analysis of human transcripts demonstrated
that differences among xenografts from infected and non-
infected mice are non-existent in non-responding tumors
and limited to a small set of up-regulated genes in
responding tumors several of them representing over-
expression of host's genes cross hybridizing to the human
platform. Most transcriptional differences in responding
tumors were instead due to the shut down of cellular
metabolisms induced by active viral infection while little
evidence of apoptotic or necrotic induction by the onco-
lytic process could be identified at this early time point
suggesting that at day 42 cells are starting to be strongly
altered in their metabolism but are still alive; this finding
correlates with the presence of viable cancer cells observed
by histopathological examination [13].
Transcriptional differences between xenografts 
responding or non-responding to systemic GLV-1h68 
administration: the mouse host's signatures
To define the host's involvement in the early phases of the
oncolytic process when tumor cells are still present and
alive [13], we analyzed HT-29 and GI-101A xenografts
using a custom-made, whole genome 36 K mouse array
platform. In this case, all 4 GI-101A xenografts excised at
day 42 from infected mice could be utilized while only 3
of 4 could be utilized for the human arrays because of deg-
radation of human mRNA in one of the regressing
xenografts. Gene expression was affected significantly
only in GI-101A xenografts (Table 2). A statistical over-
view of gene expression modulation of GI-101A
xenografts from GLV-1h68 infected grafts gave a com-
pletely opposite picture compared to the human arrays in
which a predominant down-regulation of cellular metab-
olism was observed. In particular, most mouse genes were
up regulated in xenografts excised from infected animals
suggesting that, while the metabolism of cancer cell was
declining (Figure 2C), the host response was enhanced
(Figure 3A). An F test was performed for a global compar-
ison of all experimental groups; at day 21, 1,066 genes
demarcated the differences among the 4 experimental
groups. This number increased to 1,471 by day 42 (per-
mutation test p-value < 0.001 in either case).
At day 21, IPA reveled that the 2 canonical pathways pre-
dominantly affected in GI-101A xenografts from VACV-
infected mice reflected chemokine and IFN signaling (Fig-
ure 3B). At day 42, additional canonical pathways became
affected including those associated with cellular stress
(Figure 3C). There was significant overlap among the 2
time points when only genes associated with immune
function were compared (Table 3 and 4), while most dif-
ferences between the 2 time points were observed among
genes associated with cellular stress and altered metabo-
lism. Since this manuscript focuses on the immune
aspects of oncolytic therapy, we will restrict the discussion
to immunologic signatures from now on.
In general, immunologic differences between the early
(day 21 from VACV injection) and the later (day 42) time
points were quantitative rather than qualitative, There-Page 8 of 22
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were significantly up regulated at day 21 a similar trend
could be observed at day 42 though it did not reach the
same level of statistical significance (F-test p-value <
0.001). Additionally, in the majority of cases, the host's
transcription was enhanced at the later time point when
tumor growth reached a plateau and the rejection process
was presumed to start.
Among interleukins, IL-18 and the IL-18 binding protein
played a prominent role early in the course of infection,
while later IL-15 became increasingly up regulated (Table
3 and 4). CCR2, CCR3 and CCR5 ligand chemokines
played a predominant role at day 21 while CXCR3 and
CXCR4 ligand chemokines up-regulation became more
prominent later. Among the CXCL chemokines, CXCL-
12/SDF-1 was previously associated with the rejection of
metastatic melanoma during IL-2 therapy [31] and
together with CXCL-9 through -11 chemokines in associ-
ation with the rejection of basal cell carcinomas (BCCs)
treated with TLR7 agonists [32]. ISGs and other genes
associated with the IFN signaling were among the most
Mouse host's signaturesFig re 3
Mouse host's signatures. (A) Self-organizing heat map of mouse genes differentially expressed among the 4 experimental 
groups (HT-29 and GI-101A xenografts from GLV-1h68-infected or non-infected mice) according to an F test at day 42 after 
infection. Standard filter was applied (80% presence call, 3 fold ratio cut off) that allowed 819 out of 1,066 genes at day 21 and 
1,159 out of 1,471 genes at day 42. IPA of canonical pathways over-induced in infected compared to non-infected GI-101A 
xenografts at day (B) 21 and (C) 42 based on an unpaired, two-tailed Student t test comparing infected to non-infected GI-
101A xenografts (threshold p2-value < (A) 0.001 and (B) 0.0001).Page 9 of 22
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BMC Genomics 2009, 10:301 http://www.biomedcentral.com/1471-2164/10/301Table 3: Mouse immune genes up-regulated in regressing GI-101A tumors at day 21 (F test p2-value < 0.001)
Gene LLID # Symbol Name HT-29 Control HT-29 GLV-1h68 GI-101A Control GI-101A GLV-1h68
Interleukins
16068 Il18bp interleukin 18 binding protein 0.58 0.98 1.00 5.70
16173 Il18 Il18 – interleukin 18 1.24 1.25 1.00 4.10
Chemokines
20296 Ccl2 Ccl2/MCP-1 
(human nomenclature)
1.65 2.12 1.00 10.84
20292 Ccl11 Ccl11/Eotaxin 0.64 1.10 1.00 9.47
20307 Ccl8 Ccl8/MCP-2 1.51 3.30 1.00 7.16
Cxcl11 CXCL11/-ITAC 0.82 1.04 1.00 5.69
17329 Ccl12 Ccl12/MCP-5 1.22 1.44 1.00 4.97
20306 Ccl7 Ccl7/MCP-3.MARC 0.72 0.90 1.00 4.71
Cxcl10 Cxcl10/IP-10 0.83 0.84 1.00 4.08
17329 Cxcl9 Cxcl9/Mig 0.72 0.72 1.00 3.80
20308 Ccl9 Ccl9/MRP-2/CCF18/MIP-1g 1.06 1.08 1.00 3.12
20315 Cxcl12 Cxcl12/SDF-1/PBSF 0.75 0.84 1.00 3.07
20304 Ccl5 Ccl5/RANTES 0.66 0.97 1.00 2.56
ISGs
16145 Igtp interferon gamma induced GTPase 0.50 1.13 1.00 10.11
76933 Ifi27 interferon, alpha-inducible protein 27 0.87 1.14 1.00 10.04
231655 Oasl1 2'-5' oligoadenylate 
synthetase-like 1
0.66 0.73 1.00 6.93
17857 Mx1 myxovirus (influenza virus) resistance 1 0.77 0.89 1.00 6.41
16145 Igtp interferon gamma induced GTPase 0.89 0.80 1.00 5.62
Ifi204 interferon activated gene 204 0.71 1.06 1.00 5.44
246730 Oas1a 2'-5' oligoadenylate synthetase 
1A
0.64 1.16 1.00 5.38
Iigp2 interferon inducible GTPase 2 0.63 0.83 1.00 5.25
26388 Ifi202b interferon activated gene 202B 0.54 1.17 1.00 4.61
Ifi47 interferon gamma inducible protein 47 0.54 0.67 1.00 4.56
15957 Ifit1 interferon-induced protein with 
tetratricopeptide repeats 1
1.06 0.94 1.00 4.15Page 10 of 22
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transcription 2
0.81 0.85 1.00 4.06
20846 Stat1 signal transducer and activator of 
transcription 1
0.74 0.68 1.00 4.02
16362 Irf1 interferon regulatory factor 1 0.91 1.21 1.00 3.78
65972 Ifi30 interferon gamma inducible 
protein 30
0.64 0.70 1.00 3.67
246728 Oas2 2'-5' oligoadenylate synthetase 2 1.08 1.10 1.00 3.29
Other
17067 Ly6c lymphocyte antigen 6 complex, locus C 0.90 0.99 1.00 5.77
17067 Ly6c Lymphocyte antigen 6 complex, locus C 0.95 1.12 1.00 5.27
17071 Ly6f lymphocyte antigen 6 complex, locus F 1.01 1.08 1.00 5.01
20715 Serpina3g serine (or cysteine) peptidase 
inhibitor, clade A, member 3G
0.88 0.68 1.00 4.77
18636 Cfp complement factor properdin 0.75 0.86 1.00 4.62
15331 Hmgn2 high mobility group nucleosomal 
binding domain 2
1.05 1.05 1.00 4.30
13032 Ctsc cathepsin C 0.60 0.60 1.00 4.24
64685 Nmi N-myc (and STAT) interactor 1.04 1.11 1.00 4.12
20343 Sell selectin, lymphocyte 0.95 0.75 1.00 3.91
12370 Casp8 caspase 8 0.82 0.51 1.00 3.74
16423 Cd47 CD47 antigen (Rh-related antigen, 
integrin-associated signal 
transducer)
0.89 0.83 1.00 3.72
14962 Cfb complement factor B 0.77 0.89 1.00 3.58
Pla2g7 phospholipase A2, group VII 
(platelet-activating factor 
acetylhydrolase, plasma)
0.66 0.53 1.00 3.55
13025 Ctla2b Cytotoxic T lymphocyte-associated 
protein 2 beta
0.64 1.03 1.00 3.40
18595 Pdgfra platelet derived growth factor 
receptor, alpha polypeptide
0.98 1.99 1.00 3.34
12267 C3ar1 complement component 3a 
receptor 1
0.72 0.84 1.00 3.34
16653 Kras v-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog
2.15 1.36 1.00 3.22
64138 Ctsz cathepsin Z 0.50 0.43 1.00 3.11
* In italic transcripts common to day 21 and 42; in bold those unique to each category
Table 3: Mouse immune genes up-regulated in regressing GI-101A tumors at day 21 (F test p2-value < 0.001) (Continued)Page 11 of 22
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Table 4: Mouse immune genes up-regulated in regressing GI-101A tumors at day 42 (F test p2-value < 0.001)
Gene LLID # Symbol Name HT-29 Control HT-29 GLV-1h68 GI-101A Co
Interleukins
16068 Il18bp interleukin 18 binding protein 1.31 2.18 1.00
16173 Il18 interleukin 18 1.12 1.40 1.00
16168 Il15 interleukin 15 1.02 1.51 1.00
16154 Il10ra interleukin 10 receptor alpha 0.74 0.90 1.00
Chemokines
Cxcl11 Cxcl11/I-TAC 0.92 1.75 1.00
17329 Cxcl9 Cxcl9/Mig 1.01 1.07 1.00
20304 Ccl5 Ccl5/RANTES 1.00 2.69 1.00
20308 Ccl9 Ccl9/MRP-2/CCF18/MIP-1g 1.56 3.14 1.00
20304 Ccl5 Ccl5/RANTES 1.11 2.57 1.00
20306 Ccl7 Ccl7/MARC 0.84 1.18 1.00
20315 Cxcl12 Cxcl12/SDF-1/PBSF 0.41 0.58 1.00
20301 Ccl27 Ccl27/ALP/CTACK/ILC/Eskine 1.86 1.91 1.00
20308 Ccl9 Ccl9/MRP-2/CCF18/MIP-1g 1.26 1.42 1.00
ISGs
16145 Igtp interferon gamma induced GTPase 1.15 3.31 1.00
76933 Ifi27 interferon, alpha-inducible protein 27 0.76 0.91 1.00
Ifi47 interferon gamma inducible protein 47 0.66 0.94 1.00
Iigp2 interferon inducible GTPase 2 0.64 1.41 1.00
16145 Igtp interferon gamma induced GTPase 0.70 1.28 1.00
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17857 Mx1 myxovirus (influenza virus) resistance 1 0.62 1.46 1.00
Ifi204 interferon activated gene 204 0.86 1.77 1.00
16362 Irf1 interferon regulatory factor 1 0.59 0.98 1.00
20846 Stat1 signal transducer and activator of transcription 1 0.57 0.81 1.00
20846 Stat1 signal transducer and activator of transcription 1 0.66 0.97 1.00
15957 Ifit1 interferon-induced protein with tetratricopeptide repeats 1 0.79 1.03 1.00
60440 Iigp1 interferon inducible GTPase 1 0.77 1.00 1.00
15976 Ifnar2 Interferon (alpha and beta) receptor 2 1.10 1.60 1.00
Irf5 interferon regulatory factor 5 0.53 0.70 1.00
Others
17071 Ly6f Lymphocyte antigen 6 complex, locus F 0.56 0.73 1.00
11629 Aif1 allograft inflammatory factor 1 0.90 1.33 1.00
17067 Ly6c Lymphocyte antigen 6 complex, locus C 1.24 1.22 1.00
17067 Ly6c lymphocyte antigen 6 complex, locus C 0.99 1.12 1.00
17071 Ly6f lymphocyte antigen 6 complex, locus F 0.80 0.89 1.00
20343 Sell selectin, lymphocyte 0.61 0.79 1.00
76281 Tax1bp1 Tax1 (human T-cell leukemia virus type I) 
binding protein 1
1.01 1.51 1.00
230233 Ikbkap inhibitor of kappa light polypeptide enhancer in 
B-cells
0.81 0.93 1.00
110454 Ly6a lymphocyte antigen 6 complex, locus A 0.96 0.98 1.00
13025 Ctla2b Cytotoxic T lymphocyte-associated protein 2 beta 0.68 1.20 1.00
71966 Nkiras2 NFKB inhibitor interacting Ras-like protein 2 1.07 1.27 1.00
17087 Ly96 lymphocyte antigen 96 1.13 1.43 1.00
17069 Ly6e Lymphocyte antigen 6 complex, locus E 0.77 1.15 1.00
* In italic transcripts common to day 21 and 42; in bold those unique to each category
Table 4: Mouse immune genes up-regulated in regressing GI-101A tumors at day 42 (F test p2-value < 0.001) (Continued)
BMC Genomics 2009, 10:301 http://www.biomedcentral.com/1471-2164/10/301up-regulated at either time point studied; these included
IFN-g  induced GTPase, whose expression was increased
48-fold at day 42 in GI-101A tumors from GLV-1h68-
infected animals compared to controls. IPA suggested that
the majority of up-regulated genes reflected predomi-
nantly IFN-g  stimulation, a phenomenon we have
observed in BCCs regression upon treatment with TLR-7
agonists [32] and, more generally, in association with TSD
[2]; among them, STAT-1 and IRF-1 were previously
described in association with TSD [2,31,32] and play a
central role in the signaling of IFN-g  and other pro-
inflammatory cytokines such as IL-2 and IL-15 [33].
Macrophage presence/function also played an important
role (Figure 4) and was associated with over-expression of
major histocompatiblity class II genes supporting the
presence of activated macrophages in infected GI-101A
xenografts. Furthermore, this prominent and specific infil-
tration could be substantiated by immunohistochemical
analyses that demonstrated a strong peri- and intra-
tumoral infiltration of MHC class II-expressing host's cells
surrounding virally-infected cancer cells (Figure 5).
Although there was only partial overlap between genes
up-regulated at day 21 and 42, most overlap was due to
genes related to immune function. Applying a stringent
Student t test (p2-value < 0.001) comparing infected to
non-infected GI-101A xenografts at the 2 time points,
similar results were observed; although less genes were
significantly up-regulated at day 21 (compared to the F
test) a good proportion overlapped with day 42 and those
overlapping genes were exclusively related to immune
function (Table 2). We then re-directed genes with
immune function significantly up-regulated in infected
GI-101A xenografts into self-organizing biological path-
ways using IPA; this analysis identified those genes most
tightly associated with the immunological network lead-
ing to TSD during rejection of GI-101A xenografts; while
at day 21 (Figure 6A) CCL chemokines and STAT-2 played
a central role, at day 42, IL-15, STAT-1 and IRF-1 played a
central role (Figure 6B). Interestingly, IL-18, which was
identified as playing a central role in this immune-defi-
cient mouse model; was not previously observed as a
component of the ICR in immune competent human tis-
sues affected by immune-pathology. Finally, as expected
no genes associated with B or T cell signaling or function
in the grafts were significantly up-regulated at this phase
of the immune-response against infected GI-101A
xenografts, in accordance with the biology of the host's
model system. This data suggest that at least in this model,
adaptive immunity is not necessary for TSD.
Mouse immune gene signaturesFig re 4
Mouse immune gene signatures. Self-organizing heat map based on genes selected according to macrophage (brown), nat-
ural killer cell (light green), cytokine (blue) or major histocompatiblity class II (red) annotations among those up-regulated in 
GI-101A xenografts excised from VACV-infected animals (Student t test p2-value < 0.001). Genes presented in Figure 6 as rep-
resentative of the ICR were omitted here to avoid redundancy.Page 14 of 22
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BMC Genomics 2009, 10:301 http://www.biomedcentral.com/1471-2164/10/301Based on GeneOntology annotations, we then compiled a
database of genes associated to TSD in various immune
pathologies in accordance to the ICR hypothesis [2,34].
These genes have been described as highly associated with
TSD in the context of acute allograft rejection, pathogen
clearance during acute infection and tumor rejection dur-
ing immunotherapy [2]. We displayed these a priori and
arbitrarily selected genes as a self organizing heat map
based on the data from the present study (Figure 6C). All
were specifically expressed in infected responding tumors
compared with non-infected GI-101A and the infected or
non-infected HT-29 xenografts. This display represents a
prospective validation of a universal mechanism leading
to TSD in mice as well as in humans.
Discussion
Immune-mediated TSD is the ultimate manifestation of
the effector phase of the immune response and, as we
recently argued, may follow a common final pathway
independent of the pathological circumstances leading to
its occurrence [2,34]. Thus, although the mechanisms
originating acute allograft rejection, clearance of patho-
gens during acute infection, flares of autoimmunity or
cancer regression may be different, in the end, they all
converge into a cascade of immunologic steps capable of
turning a chronic and lingering inflammatory process into
an acute and destructive one. We argued that, among the
4 axioms upon which the ICR is founded, adaptive
immune responses are neither necessary nor sufficient to
induce tissue-specific rejection but rather start a tissue-
specific reaction in cases in which such specificity is not
determined by other factors. Indeed, others have shown
that tumor rejection can be determined by innate immune
mechanisms [3] and adaptive T cell responses play a role
as helpers to stimulate more powerful innate immune
effector mechanisms [20]. Thus, in conditions in which a
switch from a chronic to an acute inflammatory process
can be induced by other factors like the immune-stimula-
tion induced by the presence of a virus in the target tissue,
adaptive immune responses may not be necessary and
Immunohistochemistry staining of MHC class II positive cellsFigure 5
Immunohistochemistry staining of MHC class II positive cells. Scale bars are equal to 1 mm and 10× magnification was 
applied. (A) 42 days after GLV-1h68 administration HT-29 (left) and GI-101A (right) xenografts were excised, sectioned and 
labeled for MHCII and vital DNA (Hoechst). In addition, GFP signals from VACV infected cells and transmission images are 
shown. (B) Overlay of MHCII and GFP signals in HT-29 tumors (left) and GI-101A tumors (right). (C) Uninfected HT-29 (left) 
and GI-101A (right) xenografts were excised at day 42 and treated identical to their infected counterparts. Tissue sections 
were stained for MHCII and vital DNA (Hoechst). As expected, no Virus-derived GFP signal could be detected.Page 15 of 22
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BMC Genomics 2009, 10:301 http://www.biomedcentral.com/1471-2164/10/301immune-mediate rejection can occur without the assist-
ance of T or B cells.
This hypothesis is suggested by some human observa-
tions. The rejection of skin cancers by the local application
of TLR-7 agonists occurs without direct evidence of adap-
tive immune responses [32,35-37]. Also renal cell carcino-
mas are as sensitive to systemic administration of IL-2 as
metastatic melanoma yet, while in the latter adaptive
immune responses are easily demonstrable, in the former,
they have been quite elusive, and most likely of secondary
significance [38,39].
Xenografts growing in primarily T cell-depleted and sec-
ondarily B cell-deficient animals provide the best evidence
that in the absence of non-self discrimination, allograft
rejection does not occur. In this model, although
xenografts by themselves do not provide sufficient pro-
inflammatory signals to induce acute inflammation, the
presence of viral replication provides the "tissue-specific
trigger" that activates the immune response. According to
our hypothesis, the ICR is activated when chronic inflam-
mation is switched into an acute one. A critical step in this
process is the expression of IFN-g  dependent pathways
probably by activated mononuclear cells; this is clearly
demonstrable in most cases in which TSD has been stud-
ied in humans by the requirement for the expression of
IRF-1 [2,31,40,41]; a transcription factor closely related to
IFN-g  signaling. IFN-a and IFN-g  regulate directly or indi-
rectly the production of CXCR3, CXCR4 and CCR5 lig-
ands among which the CXCL-9 through -11 chemokines
(Mig, IP-10/Crg-2 and ITAC), CCL5 (RANTES) and
CXCL12 (SDF-1) appear to play a prominent role [42].
Indeed, this expression pattern has been consistently
Mouse immune genes associated with the Immunologic Constant of Rejection HypothesisFig re 6
Mouse immune genes associated with the Immunologic Constant of Rejection Hypothesis. IPA self-organizing 
network based on genes with immune annotations whose expression was significantly up-regulated in VACV-infected GI-101A 
xenografts at day (A) 21 and (B) 42 from VACV-infection. (C) Self-organizing heat map based on genes associated with the 
ICR hypothesis. The genes were arbitrarily selected a priori based on previous studies as summarized in [2] and are displayed 
based on their expression in the current study without further selection.Page 16 of 22
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BMC Genomics 2009, 10:301 http://www.biomedcentral.com/1471-2164/10/301observed in most cases in which TSD was studied in the
involved tissue by transcriptional profiling [2,34] includ-
ing animal rejection models [20]. This study provides
experimental evidence that such signatures are associated
with TSD and, potentially, immune-mediate rejection
independent of the presence of adaptive immunity. More-
over, this model provides evidence that non-self discrimi-
nation plays at best a partial role in a host that cannot
eliminate xenografts unless appropriate danger signals are
provided by a pathogen [43-46]. Contrary to acute allo-
graft rejection occurring in humans [47], no B lymphocyte
signatures (CD20, immunoglobulin genes) could be
observed clearly demonstrating that reconstitution of a
potential B cell response could not have been responsible
for the inflammatory switch and the production of CXCL
and CCL chemokines [48]. Furthermore, contrary to a
similar rejection model that we presently analyzed in a
syngeneic mouse system [49], no involvement of T or B
cell signatures participated in the rejection of GI-101A
xenografts. Furthermore, contrary to the syngeneic model
of HER-2/neu-expressing mammary tumor rejection [49]
where clear up-regulation of type I and type II IFNs could
be documented, in this model ISG expression was not
directly accompanied with the over expression of IFN-a,
IFN-b or IFN-g  suggesting that, as recently demonstrated
in a cytomegalovirus model [50], stimulation of inter-
feron response genes could occur independently of de
novo synthesis of IFNs through a direct interaction of viral
proteins with cellular transcription factors.
Although most differences in the transcriptional pattern
of human cancer cells were associated with arrested or
dampened metabolism (Figure 3D) a handful of genes
were up-regulated specifically in infected GI-101A
xenografts. Among those, only IRF-7 and STAT-3 could be
proven to be specifically expressed by human cells (Figure
4B). The expression of IRF-7 is not surprising considering
the presence of replicating VACV in those cells compared
with control xenografts from non-infected animals [18],
while the expression of STAT-3 in the absence of over-
expression of STAT-1 contrasts with the analysis of host's
transcripts in which STAT-1 over-expression dominated
(Table 3). As IRF-7 and STAT-3 were also expressed by
host cells, it could be hypothesized that transfer of VACV
from cancer cells to host cells infiltrating the xenografts
reproduced patterns observed in human cancer cells,
while host's immune cells followed the classical up-regu-
lation of pro-inflammatory pathways through STAT-1,
IRF-1 signaling [18,42,51].
The over-expression of IL-18 and the IL-18-binding pro-
tein in this model is of particular interest. IL-18, originally
called IFN-g  inducing factor, has not been previously
observed by us or others as consistently associated with
TSD [2]. It is possible, that IL-18 over expression is a spe-
cific causative mechanism in this model as VACV particles
have been described as inducers of this cytokine by direct
monocyte activation through TLR signaling [52-54] a
finding that needs to be corroborated by future studies.
Contrary to IL-18, IL-15 is the most consistently observed
cytokine in association with TSD [2]. Generally, we have
observed this in association with the expression of IL-2
and, it is of interest that, in this T cell-depleted model only
this monocyte produced cytokine is present. IL-15 is criti-
cal not only in expansion of memory CD8+ T cells in mice
but also to maintain cytotoxic T cell effector functions. In
fact, VACV clearance is delayed in IL-15 -/- mice due to a
rapid loss of cytolytic function [55] most likely by natural
killer cells [56]. Thus, the role that IL-15 may play in this
immune-deficient model will need to be further investi-
gated.
In practical terms, it would be important to understand
why some tumors could be eliminated through viral onc-
olysis and/or a secondary immune rejection, while others
are resistant. It appears that the degree of viral replication
in vivo is a key determinant; however, it remains unclear
the weight that direct viral oncolysis plays compared to
immune-mediated rejection in this model. It appears that
transcriptional changes associated with viral replication
precede tumor destruction by a substantial amount of
time and they are paralleled by the activation of immune
signatures in the host, long before tissue destruction
occurs. For instance, viral replication was quite active at
day 21 in GI-101A xenografts; at the same time significant
shut down of cancer cell metabolism (Figure 3C, D) and
simultaneous activation of immune functions could be
observed at that early time point (Table 2). Yet, tumors
continued their growth at least till day 42 when their
growth started to plateau. HT-29 allowed VACV replica-
tion in vitro similarly to GI-101A, but in vivo viral replica-
tion was substantially reduced in most though not all HT-
29 xenografts (Figure 2C). This suggests that although the
baseline biological phenotype of individual cell lines can
influence viral replication, in vivo other factors may inter-
fere with viral replication, and need to be further studied.
This is suggested by the significant yet imperfect correla-
tion between in vitro and in vivo replication data and, most
importantly, by the individual variation among
xenografts originated from the same cell line that can be
permissive or non-permissive to viral replication in vivo
(HT-29 example in Figure 2C). To clarify such subtleties,
it will be necessary to investigate a larger panel of cell
lines, and assess the growth patterns of individual
xenografts. This could be achieved by the utilization of
non-invasive strategies such as fine needle aspirations that
allow direct linkage of the experimental results obtained
by transcriptional profiling to the natural or therapy-
induced history of each individual xenograft left in place
[31,57,58].Page 17 of 22
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Although xenograft infection by oncolytic VACV offers a
promising therapy of established cancer, it needs to be
taken into account that the presence of adaptive immu-
nity might change what is expected, perhaps inducing
suppressive T cell responses that could abrogate the thera-
peutic effect of the virus in natural conditions.
The rejection of GI-101A tumors seems to be mediated by
infiltrating leukocytes; thus, cancer cells not greatly
affected by the viral infection in vitro may show resistance
to in vivo oncolytic therapy. Future studies utilizing a
broader panel of cell lines will be necessary to evaluate
whether a correlation exists between in vitro replication
pattern and in vivo regression following VACV infection.
Alternatively, other factors related to the host response
within the tumor microenvironment besides the in vitro
permissiveness of cell lines may affect their in vivo per-
missiveness to VACV and/or their pattern of growth.
Indeed, the nature of the tumor microenvironment might
predict the success of the VACV therapy even though the
treatment outcome seems to be mainly correlated with the
ability of the infected tumor cells to provide the "tissue-
specific signal" to activate the immune response and
attract specific leukocytes.
In summary, this study provides the first prospective vali-
dation of a universal mechanism associated with TSD.
This information may lead to the identification of princi-
ples that could refine the treatment of cancer and chronic
infection by immune stimulation or autoimmunity and
allograft rejection through immune regulation.
Methods
Cell line culture
All cell lines except when noted were purchased from
American Type Culture Collection (Manassas). GI-101A
cells were kindly provided by Dr. A. Aller, Rumbaugh-
Goodwin Institute for Cancer Research, Inc., Plantation,
Florida whereas the 3 melanoma cell lines from distinct
cutaneous metastases were obtained from patient 888 as
previously described [24]. MDA MB-231, PANC-1, CV-1
and PC-3 cells were cultured in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and 1% antibiotic-antimycotic solu-
tion (AA) (100 U/ml penicillin G, 250 ng/ml amphoter-
icin B, 100 mg/ml streptomycin). MIA PaCa-2 cells have
been cultured under similar conditions in DMEM media
but supplemented with 12.5% FBS and 2 mM L-
glutamine. SiHa and DU-145 cells were grown in Eagle's
minimal essential medium (EMEM) which was enhanced
with 10% FBS, 1% non-essential amino acids (NEAA), 1
mM sodium pyruvate and 1% AA.
All other cells were cultured in Roswell Park Memorial
Institute medium (RPMI) supplemented with the follow-
ing compounds: A-549 and HT-29 cells (10% FBS and 1%
AA); GI-101A cells (20% FBS, 4.5 g/L glucose, 10 mM
HEPES, 1 mM sodium pyruvate, 1% AA and 4 ng/ml b-
estradiol/5 ng/ml progesterone); NCI-H1299 (10% FBS,
4.5 g/L glucose, 10 mM HEPES, 1 mM sodium pyruvate,
1% AA). OVCAR-3 culture media was prepared similarly
to GI-101A media but supplemented with 2.3 g/L glucose
instead and additional human Insulin; and 888-MEL,
1858-MEL and 1936-MEL cells (10% FBS, 1 mM HEPES,
1 mM Ciprofloxacin and L-glutamine/penicillin/strepto-
mycin). All cell cultures were carried out at 37°C under
5% CO2.
Viral construct
The construction of the mutant GLV-1h68 virus was
described previously [13]. Briefly, 3 expression cassettes
(encoding for Renilla luciferase-Aequorea GFP fusion pro-
tein, b-galactosidase and b-glucoronidase) were recom-
bined into the F14.5L, J2R and A56R loci, respectively, of
the LIVP strain viral genome.
In vitro viral replication assay
All cells were seeded in 6-well plates and infected with
GLV-1h68 at the multiplicity of infection of 0.01 as we
have previously described [13]. The infected cell cultures
were harvested in triplicate up to 72 hours post infection
(hpi). Viral titers were determined by plaque assays on
CV-1 cell monolayers and expressed as pfu/106 cells.
Virus titration of tumor tissue
GLV-1h68 infected tumors were removed at day 7, 21 and
42, weighed and homogenized in DPBS containing pro-
teinase inhibitor cocktail using MagNALyser (Roche Diag-
nostics) at a speed of 6500 for 30 s. After three freeze and
thaw cycles to release the viral particles, the samples were
sonicated and supernatants were collected by centrifuga-
tion at 1000 g for 5 min. Viral titers were determined in
duplicates by standard plaque assays using CV-1 cells.
Animal models
All mice were cared for and maintained in accordance
with animal welfare regulations under an approved proto-
col by the Institutional Animal Care and Use Committee
of LAB Research International Inc. (San Diego Science
Center, San Diego, CA). Six to 8 weeks old nude mice
(NCI:Hsd:Athymic Nude-Foxn1nu, Harlan) were inocu-
lated with 5 × 106 cells per mouse to obtain subcutaneous
xenografts as previously described [13]. Tumor growth
was measured once a week and tumor mass was reported
in mm3. Thirty days after implantation, 5 × 106 pfu of
GLV-1h68 virus in 100 ml of PBS or 100 ml of PBS alone
(control) was delivered by intravenous inoculation [13].
After inoculation with GLV-1h68 the expression of green
fluorescent protein within the tumors could be monitored
under UV-light. Twenty-one days and 42 days post inocu-Page 18 of 22
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groups were sacrificed and the tumors were excised.
Immunohistochemistry
GI-101A xenografts from GLV-1h68-infected and non-
infected mice were removed at day 42 and snap-frozen in
liquid N2, followed by fixation in 4% paraformaldehyde/
PBS pH 7.4 for 16 h at 4°C. Tissue sectioning was per-
formed as previously described [59]. MHCII-positive cells
were labeled using monoclonal rat anti-MHCII antibody
(NatuTec, Frankfurt, Germany) and Cy3-conjugated don-
key anti-rat secondary antibodies (Jackson ImmunoRe-
search, PA, USA). Hoechst 33342 (Sigma, Taufkirchen,
Germany) was used to stain nuclei. The fluorescent-
labeled sections were examined using the Leica MZ 16 FA
Stereo-Fluorescence microscope equipped with a Leica
DC500 Digital Camera (Leica, Solms, Germany). Digital
images were processed with Photoshop 7.0 (Adobe Sys-
tems, CA, USA).
Transcriptional profiling platforms
VACV-gene expression was assessed by a custom-made
VACV array platform (VACGLa520445F, Affymetrix, CA)
including 308 probes representing 219 genes that covered
the combined genome of several VACV strains (see addi-
tional file # 2), the Renilla luciferase-Aequorea green fluores-
cent fusion gene specific for GLV-1h68, and 337 human or
mouse "house keeping" genes (393 probes). Time course
analysis evaluating the in vivo effects of viral replication on
the permissive GI-101A human xenografts was performed
using a previously described custom-made 17.5 k human
cDNA array platform [29]. Human or mouse arrays covered
the complete genome of each species based on 36,000 oligos
each. We have previously observed that the use of species-
specific cDNA arrays as well as oligo probes can distinguish
the expression patterns in mixed cell populations in which
human tissues (cancer cells) are infiltrated with host cells.
This is because of a lack or reduced cross-hybridization
between non-related species compared to closely related
ones such as primate to primate comparisons [13]. Although
partial cross-hybridization may occur this can be detected
and eliminated by applying an appropriate intensity signal
cutoff. Since cDNA arrays contain probes of relatively large
size (600 to 2,000 bases), to increase the specificity of the
hybridization, we tested the same material on custom-made
36 kb oligo array platforms constituted of 70-base-length
oligo-probes as well as cDNA probes using identical statisti-
cal parameters. With few exceptions (discussed in the results
section) results were concordant between platforms and will
be presented, thereof, in either format while comprehensive
data are accessible through GEO.
Total RNA isolation and amplification
Total RNA (tRNA) from excised tumors was isolated after
homogenization using Trizol reagent according to the
manufacturer's instructions. tRNA from tissue cultures
was isolated with the Qiagen RNeasy Mini kit and the
quality of obtained tRNA was tested with the Agilent Bio-
analyzer 2000 (Agilent Technologies). For expression
studies based on cDNA and oligo array techniques, tRNA
was amplified into antisense RNA (aRNA) as previously
described [60,61].
Mouse reference RNA was prepared by homogenization
and pooling of selected mouse tissues (lung, heart, mus-
cle, kidneys, liver and spleen) from 3 female C57Bl/6
mice. Reference for human arrays was obtained by pool-
ing PBMCs from 4 normal donors. Both, human and
mouse reference tRNA was amplified into antisense RNA
in large amounts [60,61]. Five mg tRNA of selected tumor
and cell samples were amplified according to the Affyme-
trix manual using the GeneChip® One-Cycle Target Labe-
ling and Control kit.
Microarray performance and statistical analysis
Array quality was documented as previously described
[29]. For 36 k whole genome mouse and human array per-
formances both reference and test aRNA were directly
labeled using ULS aRNA Fluorescent Labeling kit
(Kreatech) with Cy3 for reference and Cy5 for test samples
and co-hybridized to the slides [49]. 17 k human cDNA
arrays were carried out as described according to our
standard method for labeling and array hybridization
[62]. A customized VACV-GLV-1h68 Affymetrix expres-
sion array was specifically prepared for this study. Ampli-
fied RNA from tumor or cell samples was handled
according to the manufacture's instructions for eukaryotic
sample processing and hybridized to the arrays. After a 16
h incubation in the hybridization oven at 45°C, the arrays
were washed and stained in the Fluidics station using the
GeneChip® Hybridization, Wash, and Stain Kit.
The data was uploaded to the mAdb databank http://nci
array.nci.nih.gov and further analyzed using BRBArray-
Tools developed by the Biometric Research Branch,
National Cancer Institute http://linus.nci.nih.gov/BRB-
ArrayTools.html[63] and Cluster and TreeView software
[64]. Multiple dimensional scaling was performed on the
BRB-array tool.
Data retrieved from the Affymetrix platform was normal-
ized using median over entire array as reference because of
single color labeling technology. For all array type's unsu-
pervised analysis was used for class confirmation using
the Stanford Cluster program (80% gene presence across
all experiments and at least 3-fold ratio change) and
Treeview program for visualization. Gene ratios were aver-
age corrected across experimental samples and displayed
according to uncentered correlation algorithm. Class
comparison was performed using parametric unpaired
Student's t test or 3-way ANOVA to identify differentially
expressed genes among GLV-1h68 infected and unin-Page 19 of 22
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ent significance cutoff levels as demanded by the
statistical power of each test. Subsequent filtering (80%
gene presence across all experiments and at least 3-fold
ratio change) narrowed down the number of genes that
were expressed differentially between experimental
groups.
Statistical significance and adjustments for multiple test
comparisons were based on univariate and multivariate
permutation test as previously described.
No quantitative polymerase chain reaction-based (q-PCR)
validation of the gene sets identified in this study was per-
formed since we have previously extensively shown that
the present method for RNA amplification is robust and
yields results comparable to those obtained by qPCR
[29,65,66], and the primary purpose of the analysis was to
evaluate general patterns of expression rather than identi-
fying and characterize single gene expression levels.
Gene function interpretation was based on GeneOntology
software while pathway analysis was based on Ingenuity
Pathways Analysis software.
Sequence analysis
To determine species origin of selected genes we designed
primers flanking array probe positions within coding
regions (Additional file 2). Gene transcript sequences
were obtained from Ensembl database. To rule out any
cross hybridizations we did extensive BLAST search of the
designed primer sequences.
Specific primers were used to reverse transcribe 500 ng
tRNA from excised tumors and amplify the messages sub-
sequently. The resulting PCR products were analyzed with
the Agilent Bioanalyzer to proof their length and presence.
All amplicons have been cleaned up with ExoSAP-IT®
(United States Biomedical/Affymetrix, Cleveland, OH,
USA) and transferred to the sequencing reactions per-
formed with BigDye® . Before loading into the 48-capillary
3730 DNA Analyzer (Applied Biosystem, Foster City, CA,
USA) all reactions were purified with DyeEx 2.0 Spin Kit
(Qiagen, Valencia, CA, USA).
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